Publications by authors named "Daniel Gipe"

Claim this Profile
A
ANGPTL3 Inhibition With Evinacumab Results in Faster Clearance of IDL and LDL apoB in Patients With Homozygous Familial Hypercholesterolemia-Brief Report.
Laurens F Reeskamp, John S Millar, Liya Wu, Hans Jansen, Dewi van Harskamp, Daniel A Gipe

Arterioscler Thromb Vasc Biol· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized study investigating the safety, tolerability, and pharmacokinetics of evinacumab, an ANGPTL3 inhibitor, in healthy Japanese and Caucasian subjects.
Mariko Harada-Shiba, Shazia Ali, Daniel A Gipe, Evelyn Gasparino, Vladimir Son

Atherosclerosis· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evinacumab for Homozygous Familial Hypercholesterolemia.
Frederick J Raal, Robert S Rosenson, Laurens F Reeskamp, G Kees Hovingh, John J P Kastelein, Daniel A Gipe

N Engl J Med· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Functional Analysis of LDLR (Low-Density Lipoprotein Receptor) Variants in Patient Lymphocytes to Assess the Effect of Evinacumab in Homozygous Familial Hypercholesterolemia Patients With a Spectrum of LDLR Activity.
Poulabi Banerjee, Kuo-Chen Chan, Michel Tarabocchia, Asier Benito-Vicente, Ana C Alves, Daniel A Gipe

Arterioscler Thromb Vasc Biol· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhibition of Angiopoietin-Like Protein 3 With a Monoclonal Antibody Reduces Triglycerides in Hypertriglyceridemia.
Zahid Ahmad, Poulabi Banerjee, Sara Hamon, Kuo-Chen Chan, Aurelie Bouzelmat, Daniel A Gipe

Circulation· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 monoclonal antibody alirocumab vs placebo in patients with heterozygous familial hypercholesterolemia.
John J P Kastelein, G Kees Hovingh, Gisle Langslet, Marie T Baccara-Dinet, Daniel A Gipe

J Clin Lipidol· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genetic and Pharmacologic Inactivation of ANGPTL3 and Cardiovascular Disease.
Frederick E Dewey, Viktoria Gusarova, Richard L Dunbar, Colm O'Dushlaine, Claudia Schurmann, Daniel Gipe

N Engl J Med· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
ANGPTL3 Inhibition in Homozygous Familial Hypercholesterolemia.
Daniel Gaudet, Daniel A Gipe, Robert Pordy, Zahid Ahmad, Marina Cuchel

N Engl J Med· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Open-label therapy with alirocumab in patients with heterozygous familial hypercholesterolemia: Results from three years of treatment.
Robert Dufour, Jean Bergeron, Daniel Gaudet, Robert Weiss, G Kees Hovingh, Daniel A Gipe

Int J Cardiol· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: The ODYSSEY ALTERNATIVE randomized trial.
Patrick M Moriarty, Paul D Thompson, Christopher P Cannon, John R Guyton, Jean Bergeron, Daniel A Gipe

J Clin Lipidol· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia.
John J P Kastelein, Henry N Ginsberg, Gisle Langslet, G Kees Hovingh, Richard Ceska, Daniel A Gipe

Eur Heart J· November 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of alirocumab, a monoclonal antibody to PCSK9, in statin-intolerant patients: design and rationale of ODYSSEY ALTERNATIVE, a randomized phase 3 trial.
Patrick M Moriarty, Terry A Jacobson, Eric Bruckert, Paul D Thompson, John R Guyton, Daniel Gipe

J Clin Lipidol· September 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy of alirocumab 150 mg every 2 weeks, a fully human proprotein convertase subtilisin/kexin type 9 monoclonal antibody: A Phase II pooled analysis.
Michael J Koren, Eli M Roth, James M McKenney, Daniel Gipe, Corinne Hanotin

Postgrad Med· March 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of alirocumab, a monoclonal proprotein convertase subtilisin/kexin 9 antibody, on lipoprotein(a) concentrations (a pooled analysis of 150 mg every two weeks dosing from phase 2 trials).
Daniel Gaudet, Dean J Kereiakes, James M McKenney, Eli M Roth, Corinne Hanotin, Daniel Gipe

Am J Cardiol· September 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Serum PCSK9 Levels Distinguish Individuals Who Do Not Respond to High-Dose Statin Therapy with the Expected Reduction in LDL-C.
Beth A Taylor, Gregory Panza, Linda S Pescatello, Stuart Chipkin, Daniel Gipe

J Lipids· August 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of alirocumab in patients with heterozygous familial hypercholesterolemia not adequately controlled with current lipid-lowering therapy: design and rationale of the ODYSSEY FH studies.
John J P Kastelein, Jennifer G Robinson, Michel Farnier, Michel Krempf, Gisle Langslet, Daniel A Gipe

Cardiovasc Drugs Ther· June 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis